| Summary of Net Loss Attributable to Common Stockholders |
The following tables present the calculation of basic and diluted net income (loss) per share (in thousands, except share and per share amounts): | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | 2025 | | 2025 | | 2024 | | Redeemable Common Stock | | Common Stock | | Common Stock | | Numerator: | | | | | | | Allocation of net income attributable to common stockholders | $ | 79 | | | $ | 2,946 | | | $ | 3,274 | | | Accretion on convertible preferred stock | — | | | (847) | | | (1,328) | | | Accretion on redeemable common stock | 21 | | | (21) | | | — | | | Allocation of net income to participating securities | $ | (14) | | | $ | (330) | | | $ | (661) | | | Allocated net income attributable to common stockholders | $ | 86 | | | $ | 1,748 | | | $ | 1,285 | | | Denominator: | | | | | | | Weighted average common shares outstanding, basic | 562,500 | | 15,383,287 | | 8,740,059 | | Net income per share attributable to common stockholders, basic | $ | 0.15 | | | $ | 0.11 | | | $ | 0.15 | |
| | | | | | | | | | | | | | | | | | | Three Months Ended March 31, | | 2025 | | 2025 | | 2024 | | Redeemable Common Stock | | Common Stock | | Common Stock | | Numerator: | | | | | | | Allocation of net income attributable to common stockholders | $ | 79 | | | $ | 2,946 | | | $ | 3,274 | | | Accretion on convertible preferred stock | — | | | (847) | | | (1,328) | | | Accretion on redeemable common stock | 21 | | | (21) | | | — | | | Allocation of net income to participating securities | — | | | (330) | | | — | | | Effect of dilutive securities | — | | | — | | | (6,809) | | | Allocated net income (loss) attributable to common stockholders | $ | 100 | | | $ | 1,748 | | | $ | (4,863) | | | Denominator: | | | | | | | Weighted average common shares outstanding, basic | 562,500 | | 15,383,287 | | 8,740,059 | | Effect of dilutive securities | 125,000 | | 0 | | 877,766 | | Weighted average common shares outstanding, diluted | 687,500 | | 15,383,287 | | 9,617,825 | | Net income (loss) per share attributable to common stockholders, diluted | $ | 0.15 | | | $ | 0.11 | | | $ | (0.51) | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The following table summarizes the common stock equivalents of potentially dilutive outstanding securities excluded from the computation of diluted net loss per share due to their anti-dilutive effect: | | | | | | | | | | | | | March 31, | | 2025 | | 2024 | | Stock options | 377,012 | | | 463,168 | | | RSUs | 1,450,316 | | | 1,526,327 | | | RSAs | 107,636 | | — | | PSUs | 56,391 | | | 71,428 | | | ESPP shares committed | 51,073 | | | 19,388 | | | Common stock warrants | 11,099,708 | | | 3,102,591 | | | Preferred stock | 2,872,668 | | | 5,200,802 | | | Total | 16,014,804 | | | 10,383,704 | |
|